NCT00100334View on ClinicalTrials.gov

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

August 31, 2005

Conditions
Alzheimer's Disease
Interventions
DRUG

PPI-1019 (APAN)

Trial Locations (1)

92675

Silverado Senior Living, San Juan Capistrano

Sponsors
All Listed Sponsors
lead

PRAECIS Pharmaceuticals Inc.

INDUSTRY